Cortexyme Announces Upcoming Data Presentations at the Alzheimer’s Association International Conference 2019
- Company’s novel approach to addressing Alzheimer’s to be featured in two Developing Topics abstracts at AAIC
In a Developing Topics poster (P4-663), researchers will detail the rationale for and design of the GAIN trial, the recently initiated Phase 2/3 study of Cortexyme’s lead gingipain inhibitor, COR388, in subjects with mild to moderate Alzheimer’s disease (AD). The GAIN trial is based on growing evidence that points to a key role for Porphyromonas gingivalis, the bacterium most commonly associated with chronic periodontal disease, in the development of AD, based on the identification of the bacteria in the brain of AD patients and its ability to cause neurodegeneration, inflammation, and other pathology associated with Alzheimer’s in animal models.
“We’re in a critical moment for Alzheimer’s drug development, and patients deserve new approaches driven by solid science,” said
A second Developing Topics poster (P4-542) will examine the utility of a speech-based digital biomarker for tracking disease progression and treatment response to COR388. This tool, developed by
The schedule of
[Abstract P4-663]: “Initiation of the Phase 2/3 GAIN trial of COR388, a novel bacterial virulence factor inhibitor for the treatment of Alzheimer’s Disease (AD) based on Phase 1 a/b safety, PK, biomarker and efficacy data”
Session: Developing Topics – Poster Presentations
Poster presented
[Abstract P4-542] “Utility of speech-based digital biomarkers for evaluating disease progression in clinical trials of Alzheimer's disease”
Session: Developing Topics – Poster Presentations
Poster presented
About
Forward-Looking Statements
Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “expect,” “believe,” “will,” “may,” “should,” “estimate,” “project,” “outlook,” “forecast” or other similar words. Forward-looking statements are based on Cortexyme’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties described in the section titled “Risk Factors” in the final prospectus related to Cortexyme’s initial public offering filed with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20190710005435/en/
Source:
Hal Mackins
For Cortexyme, Inc.
hal@torchcomllc.com
(415) 994-0040